Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 5,658 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO John Cox sold 5,658 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the transaction, the chief executive officer directly owned 357,507 shares of the company’s stock, valued at approximately $6,749,732.16. This represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $20.31 on Wednesday. The business’s fifty day simple moving average is $24.82 and its 200 day simple moving average is $20.49. The firm has a market capitalization of $3.79 billion, a P/E ratio of -6.10 and a beta of 1.08. Dyne Therapeutics, Inc. has a 12 month low of $11.92 and a 12 month high of $27.31. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on DYN shares. Wall Street Zen downgraded shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Royal Bank Of Canada raised their price target on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, July 30th. Sanford C. Bernstein lifted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research note on Friday, May 15th. Finally, Cantor Fitzgerald started coverage on Dyne Therapeutics in a report on Thursday, July 23rd. They set an “overweight” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Institutional Trading of Dyne Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. grew its holdings in Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after buying an additional 14,727,667 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Dyne Therapeutics in the second quarter worth about $275,500,000. Jupiter Topco LLC bought a new position in shares of Dyne Therapeutics in the second quarter valued at approximately $266,634,000. State Street Corp boosted its position in shares of Dyne Therapeutics by 27.0% in the fourth quarter. State Street Corp now owns 6,692,745 shares of the company’s stock valued at $130,910,000 after acquiring an additional 1,423,828 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its stake in Dyne Therapeutics by 45.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock valued at $101,164,000 after acquiring an additional 1,618,000 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne announced that it will present additional six- and 12-month data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) at the World Muscle Society and AANEM meetings beginning September 29-30. The data will include comparisons with a matched natural-history cohort and updated safety results. Dyne ACHIEVE trial data announcement
• Positive Sentiment: The ACHIEVE registrational expansion cohort is fully enrolled, and Dyne expects topline results in the first quarter of 2027. DYNE-101 also has FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, supporting the potential for an expedited development path. Quiver Quantitative ACHIEVE summary
• Neutral Sentiment: Call-option activity surged, with traders purchasing approximately 20,532 calls versus average daily volume of about 464. This may reflect speculative expectations for a rebound or upcoming data, but options activity does not confirm a fundamental improvement.
• Negative Sentiment: Reports said DYN fell heavily after a rival DM1 drug failed in Phase 3. Investors appear concerned that the setback could signal clinical or commercial risks for the DM1 field, even though Dyne’s own upcoming one-year data have not yet been released. RTT News report on rival DM1 failure
• Negative Sentiment: Several executives, including CEO John Cox, reported stock sales. The transactions were made to cover tax withholding on vested equity awards and were relatively small compared with their remaining holdings, limiting their direct significance, but the cluster of sales may add to cautious sentiment.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.